

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

King, PT;Sharma, R;O'Sullivan, KM;Callaghan, J;Dousha, L;Thomas, B;Ruwanpura, S;Lim, S;Farmer, MW;Jennings, BR;Finsterbusch, M;Brooks, G;Selemidis, S;Anderson, GP;Holdsworth, SR;Bardin, PG

Title:

Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung

Date:

2017-12-01

Citation:

King, P. T., Sharma, R., O'Sullivan, K. M., Callaghan, J., Dousha, L., Thomas, B., Ruwanpura, S., Lim, S., Farmer, M. W., Jennings, B. R., Finsterbusch, M., Brooks, G., Selemidis, S., Anderson, G. P., Holdsworth, S. R. & Bardin, P. G. (2017). Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung. *Scientific Reports*, 7 (1), <https://doi.org/10.1038/s41598-017-12474-5>.

Persistent Link:

<https://hdl.handle.net/11343/255179>

License:

[CC BY](#)

SCIENTIFIC REPORTS



OPEN

Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung

Paul T. King^{1,2}, Roleen Sharma^{1,2}, Kim M. O'Sullivan², Judy Callaghan³, Lovisa Dousha⁴, Belinda Thomas^{1,5}, Saleela Ruwanpura⁵, Steven Lim², Michael W. Farmer¹, Barton R. Jennings¹, Michaela Finsterbusch², Gavin Brooks⁵, Stavros Selemidis⁶, Gary P. Anderson⁴, Stephen R. Holdsworth² & Philip G. Bardin^{1,5}

Our aim was to investigate if deoxyribonuclease (DNase) 1 is a potential therapeutic agent to reduce pathogenic effects of cigarette smoke exposure in the lung. Cigarette smoke causes protease imbalance with excess production of proteases, which is a key process in the pathogenesis of emphysema. The mechanisms responsible for this effect are not well-defined. Our studies demonstrate both *in vitro* and *in vivo* that cigarette smoke significantly increases the expression of neutrophil and macrophage extracellular traps with coexpression of the pathogenic proteases, neutrophil elastase and matrix metalloproteinases 9 and 12. This response to cigarette smoke was significantly reduced by the addition of DNase 1, which also significantly decreased macrophage numbers and lung proteolysis. DNase 1, a treatment currently in clinical use, can diminish the pathogenic effects of cigarette smoke.

Cigarette smoke exposure induces chronic inflammation in the lung, as well as causing widespread extrapulmonary manifestations. Lung inflammation is the primary cause of emphysema and chronic obstructive pulmonary disease (COPD) and persists after smoking cessation^{1,2}. Currently available anti-inflammatory therapy for emphysema and chronic obstructive pulmonary disease (COPD) is only partially effective and does not reverse the underlying processes³.

Proteases are produced in the lung and have an important role in tissue remodelling. Protease imbalance is considered to be a cardinal pathway in the pathogenesis of emphysema and COPD, as well other chronic inflammatory lung diseases including cystic fibrosis (CF) and bronchiectasis⁴⁻⁷. Macrophages express proteases, including matrix metalloproteinase (MMP) 9 and MMP12 and neutrophils express neutrophil elastase (NE). The excessive and sustained production of proteases and/or deficiency of inhibitors (e.g. alpha-1 antitrypsin)^{4,8} results in protease imbalance and this may mediate the development of lung pathology^{4-7,9,10}. Cigarette smoke is a stimulus known to induce protease expression but the mechanisms involved have not been clearly defined.

One mechanism linked to protease expression and inflammation is extracellular trap formation. Extracellular traps are produced by neutrophils (NETs) and are composed of extracellular processed chromatin bound to granular and selected proteins (e.g. granule proteases). NETs are most commonly expressed as an inflammatory response to infection (especially bacteria) and have an important role in host defence. The production of reactive oxygen species (ROS) has a primary role in initiating their generation^{11,12}. The colocalisation of proteases with chromatin, citrullination of histone (H3Cit) and the production of peptidylarginase deiminase (PAD) 4 are specific features of NETosis, which distinguish it from other cellular pathways such as apoptosis¹³⁻¹⁷. Recently it has been recognised that other leukocytes may also produce extracellular traps including macrophages (METs)^{12,18,19}. METs are not a well-defined pathology in the literature but one characteristic feature of extracellular traps is that production is dismantled extracellularly by the addition of deoxyribonuclease (DNase) 1. DNase I degrades

¹Monash Lung and Sleep, Monash Medical Centre, Melbourne, Australia. ²Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia. ³Monash Micro Imaging, Monash University, Melbourne, Australia. ⁴Department of Pharmacology, University of Melbourne, Melbourne, Australia. ⁵Hudson Institute of Medical Research, Melbourne, Australia. ⁶Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia. Paul T. King and Roleen Sharma contributed equally to this work. Correspondence and requests for materials should be addressed to P.T.K. (email: paul.king@monash.edu)

extracellular chromatin and is currently used as a clinical treatment to improve sputum clearance by degrading host and bacterial DNA in the airways of patients with cystic fibrosis (CF).

We hypothesized that cigarette smoke induces protease expression via macrophage and neutrophil extracellular trap formation. We also postulated that the expression of NETs and METs and consequent pathogenic effects would be reduced by the addition of DNase 1.

Results

Cigarette smoke induces the expression of METs. We first assessed whether cigarette smoke extract (CSE) induced MET expression *in vitro*. Alveolar macrophages were obtained by bronchoalveolar lavage (BAL) from patients undergoing bronchoscopy (Table S1 in the Supplementary Information). Alveolar macrophages were exposed to CSE for one hour before being fixed and phenotyped with specific markers and analysed for MET expression by confocal microscopy (Table S2). MET expression was measured by the extracellular production of chromatin and colocalisation with the proteases MMP9 and MMP12 (representative images are shown in Fig. 1A and B). CSE induced an increase in MET expression ($P < 0.001$, Fig. 1C). To further characterise METs we used an additional method to identify MET formation by demonstrating the coexpression of H3Cit with extracellular chromatin. CSE upregulated MET formation ($P < 0.001$, Figs 1D and S1 in the online data supplement). We further characterised MET formation by demonstrating colocalisation of chromatin/H3Cit with either MMP9 or PAD2 (Figures S1 and S2 in the Supplementary Information).

In a subgroup analysis of the patients from whom BAL was obtained, subjects with a significant smoking history (>10 pack-years) and emphysema were compared to subjects without a significant smoking history and no known lung disease. Both groups demonstrated upregulation of MET production ($P < 0.05$, Figure S3).

To examine MET expression *in vivo*, mice were exposed to cigarette smoke for 4 days and then BAL macrophages were obtained. METs were defined by the colocalisation of extracellular chromatin, MMP9 and H3Cit. Cigarette smoke increased the production of METs from BAL macrophages *in vivo* ($P < 0.001$, Figs 1E,F and S4). We also measured the production of METs in the lungs of smoke-exposed mice and detected an increase in MET expression ($P < 0.001$, Figs 1G,H and S5). Thus both *in vitro* and *in vivo*, cigarette smoke induces MET production with protease coexpression.

Cigarette smoke induces the expression of NETs. We used an established method to define NETs with coexpression of extracellular chromatin, the protease NE, H3Cit and PAD4 (PAD4 is present in neutrophils, whilst PAD2 is more prominent in macrophages), (representative images are shown in Figs 2A and S6). CSE significantly upregulated NET expression *in vitro* in peripheral blood neutrophils obtained from healthy human controls ($P = 0.007$, Fig. 2B). We used blood neutrophils because numbers of neutrophils in BAL were generally too low to examine expression of NETs.

Another method that has been used to define the expression of NETs is using the non-cell permeable DNA dye SYTOX green¹¹. We developed a flow cytometry method using SYTOX green and demonstrated that CSE upregulated NET expression in human neutrophils ($P = 0.005$, Fig. 2C and D). We were not able to use this SYTOX method successfully for the demonstration of METs as the macrophages were adherent after stimulation and could not be removed.

We also confirmed upregulated NET expression in lung tissue from mice that had been exposed to cigarette smoke ($P < 0.001$, Fig. 2E,F and Figure S7). The numbers of METs were approximately 5-fold higher than the numbers of NETs in the lung tissue in this model (Fig. 2G).

Comparison of METs and NETs. There is minimal published literature that compares METs and NETs. Our previous published data showed that the common lung bacterium nontypeable *Haemophilus influenzae* induced a higher percentage of neutrophils to produce extracellular traps when compared to macrophages¹⁹. In the current study there were notable differences in morphology between NETs and METs. The length of extracellular traps in the human samples was measured showing that NETs had longer extensions of extracellular chromatin ($P = 0.029$, Figure S8A). An example of this can be seen when comparing the image of a NET in Fig. 2A with a MET in Fig. 1B. Neutrophils and macrophages have different roles in host defence and this may be reflected in the particular characteristics of their respective extracellular traps.

The published literature highlights the critical role of the oxidative burst with ROS production in the generation of NETs^{11–13}. Cigarette smoke causes oxidative stress; it contains large numbers of oxygen radicals and also induces an inflammatory response by phagocytes with subsequent ROS production. CSE increased intracellular ROS levels in human macrophages ($P = 0.041$, Figure S9A) and neutrophils ($P = 0.031$, Figure S9B), and this process is likely to have a key role in the development of extracellular traps. ROS production was higher in CSE exposed neutrophils than in macrophages ($P = 0.043$, Figure S8B).

DNase 1 reduces the expression of extracellular traps, lung macrophage numbers and lung proteolysis. DNase 1 has been shown to dismantle extracellular trap formation^{11,12}. The addition of DNase 1 decreased cigarette smoke-induced MET expression *in vitro* ($P < 0.001$, Fig. 3A and B) and *in vivo* ($P < 0.001$, Fig. 3C and D). DNase 1 also decreased cigarette smoke-induced NET expression, both *in vitro* ($P = 0.017$, Fig. 3E), ($P = 0.006$, Fig. 3F) and *in vivo* ($P = 0.041$, Fig. 3G).

Cigarette smoke increased the numbers of macrophages in mouse lung tissue ($P < 0.001$) and the addition of DNase reduced numbers of macrophages ($P < 0.001$, Fig. 4A). Cigarette smoke increased numbers of neutrophils in lung tissue ($P = 0.011$) but DNase did not appear to reduce neutrophils (Fig. 4B).

To provide further confirmation of the specific activities of DNase, we included studies of a vehicle control (with no DNase) in smoke-exposed mice. The vehicle control did not cause a significant reduction in lung METs, NETs or macrophages (Figure S10).




Figure 1. Cigarette smoke exposure induces formation of macrophage extracellular traps. Cigarette smoke extract (CSE) induces macrophage extracellular trap (MET) formation in human bronchoalveolar (BAL) macrophages *in vitro* (A–D). (A) Representative image shows MET formation as characterised by extracellular chromatin, matrix metalloproteinase (MMP) 9, MMP12 and merged image; insert shows isotype control. Scale bars = 30 μ m. (B) High resolution image of MET. Scale bars = 10 μ m. (C) MET expression as characterised by extracellular chromatin, MMP9 and 12 ($n = 20$ individuals). (D) MET expression as characterised by extracellular chromatin and citrullinated histone (H3Cit), ($n = 13$). Exposure to cigarette smoke induces MET expression in murine lung *in vivo* (E–H). (E) Image shows MET formation by BAL macrophages. Scale bar = 10 μ m. (F) MET expression by murine BAL macrophages ($n = 13$). (G) Image of MET in murine lung tissue. Scale bar = 20 μ m. (H) MET expression by lung tissue macrophages ($n = 10$). Results are shown as air (or control) and smoke exposure (*in vitro* CSE or *in vivo* cigarette smoke exposure).




Figure 2. Cigarette smoke exposure induces formation of neutrophil extracellular traps. CSE induces neutrophil extracellular trap (NET) formation in human peripheral blood neutrophils *in vitro* (A–D). (A) Representative image shows NET formation as characterised by staining for extracellular chromatin, H3Cit, peptidylarginine deiminase (PAD) 4 and neutrophil elastase (NE). Scale bar = 20 μ m. (B) NET expression in blood neutrophils ($n = 8$ individuals). (C) A flow cytometry method was also developed to measure NET production, with SYTOX green staining for extracellular chromatin production and eFluor as a marker of cell death. Dot plot shows NET expression as characterised by positive staining for SYTOX green and negative for eFluor. (D) NET expression by neutrophils demonstrated using flow cytometry ($n = 8$). Exposure to cigarette smoke induces NET expression in mice *in vivo* (E,F). (E) Image shows NET formation in lung tissue. Scale bar = 10 μ m. (F) NET expression in lung tissue ($n = 10$). (G) In lung tissue, cigarette smoke induced a higher number of METs than NETs.




Figure 3. Deoxyribonuclease 1 disrupts macrophage and neutrophil extracellular trap formation. The addition of deoxyribonuclease (DNase) 1 reduces the expression of cigarette smoke-induced METs. MET expression *in vitro* (A,B): (A) CSE-induced human BAL METs (chromatin/MMP9/12), ($n = 20$), and (B) CSE-induced human BAL METs (chromatin/H3Cit), ($n = 14$). MET expression *in vivo* in murine lung (C,D): (C) BAL METs ($n = 10$), and (D) lung tissue METs ($n = 10$). The addition of DNase 1 reduces the expression of cigarette smoke-induced NETs (E,F): (E) CSE-induced human blood NETs ($n = 8$), and (F) NETs as characterised using flow cytometry ($n = 8$). NET expression *in vivo* in mice: (G) lung tissue NETs ($n = 10$). Results are shown as smoke exposure (*in vitro* CSE or *in vivo* cigarette smoke exposure) and the effect of the addition of DNase 1 on this exposure.




Figure 4. Deoxyribonuclease 1 reduces lung macrophages and areas of proteolysis. Cigarette smoke increases numbers of macrophages and neutrophils and the area of the lung with proteolysis in a murine model *in vivo*. The addition of DNase 1 reduces macrophage numbers and lung proteolysis. (A) Number of macrophages in the lung ($n = 10$). (B) Number of neutrophils in the lung ($n = 10$). The area of lung demonstrating area of proteolytic change was assessed using *in situ* zymography. (C) Shows staining for chromatin (blue) and staining for proteolysis (green). (D) Area of lung with proteolysis ($n = 10$).

Zymography can be used to define the presence of functionally activated proteases. *In situ* zymography enables the localisation and quantitation of matrix-degrading protease activity in histological sections²⁰. We used *in situ* zymography to demonstrate that cigarette smoke in mouse lung tissue increased the area of lung with proteolysis ($P = 0.012$) and that this was reduced by the addition of DNase ($P = 0.048$, Figs 4C,D and S11). The dose of DNase we used for these experiments did not have a major effect on cell viability (Figure S12)

Discussion

We have shown both *in vitro* and *in vivo*, that cigarette smoke is a potent inducer of extracellular trap formation by lung macrophages and neutrophils. METs and NETs express proteases including macrophage metalloproteinases 9 and 12 and neutrophil elastase. Importantly, these proteases have been shown to have a key role in the development of protease imbalance, lung inflammation and lung pathology in COPD. Extracellular trap formation induced by cigarette smoke was effectively dismantled by DNase 1.

COPD is characterised by two primary pathogenic processes that generally occur together; emphysema and chronic bronchitis. Proteases have an important role in the digestion of the extracellular matrix and contribute to remodelling of lung tissue. Protease imbalance has been most clearly demonstrated in the pathogenesis of emphysema. It also has a key role in other inflammatory lung conditions including cystic fibrosis and bronchiectasis⁴⁻⁷. This imbalance is characterised by the overproduction of pathogenic lung proteases and/or deficiency of antiproteases (e.g. alpha-1 antitrypsin). Key proteases that have been identified in this context include neutrophil elastase and MMP 1, 9 and 12. MMP12 knockout mice are protected from emphysema¹⁰ and patients with polymorphisms of MMP9 have increased risk of emphysema²¹. Proteases are present inside immune cells such as macrophages and neutrophils. Smoking has been shown to induce extracellular expression of active proteases in the lung but the mechanisms involved are poorly understood.

Neutrophil extracellular traps are composed of extracellular processed chromatin bound to granular and selected proteins^{11,12,22}. NETs are primarily induced in response to infection (predominantly bacteria) and are generally pro-inflammatory. In addition to their role in protection against infection, NETs have been described in noninfectious disease such as autoimmune conditions (e.g. systemic lupus erythematosus), in thrombosis and in response to the mitogen phorbol myristate acetate^{11,12,23}. There have been several recent reports which have

described NETs occurring in patients with COPD^{24–26}, with traps being demonstrated both in stable and exacerbated COPD and correlating with inflammatory markers. Two recent studies have described that nicotine induces NETosis *in vitro*. Both studies demonstrated in healthy human controls that nicotine acts on nicotinic acetylcholine receptors on peripheral blood neutrophils to induce NET formation^{27,28}. Nicotinic receptors do not have a clearly defined direct role on lung phagocyte function in the lung. The nicotinic pathway acts in the nervous system (and is responsible for the addictive effect of nicotine). The nicotinic pathway acts on the lung via the vagus nerve having an anti-inflammatory effect with downregulation of inflammatory cytokine production²⁹. There are no reports to our knowledge describing an association between smoking and extracellular trap formation in the lung and the potential influence of DNase 1 on this process.

The production of extracellular traps also occurs in other cell types including macrophages^{12,18}. Macrophages have similar properties to neutrophils with production of ROS in response to infection and the production of proteases. We have previously described MET formation in human BAL macrophages after exposure to the common respiratory bacterium, nontypeable *Haemophilus influenzae* (NTHi)¹⁹. In the current study we have demonstrated that cigarette smoke induced both NET and MET formation with pathogenic protease coexpression. The production of METs was approximately 5-fold higher than NET production in response to cigarette smoke.

Although the primary aim of this study was to investigate if cigarette smoke induced the formation of extracellular traps, we also found that subjects without a significant smoking history (and no definable lung disease) and those with a significant smoking history (and evidence of emphysema) had an increase in MET expression on exposure to cigarette smoke. The current studies were not powered to ascertain if subjects who smoke and have evidence of emphysema have higher MET expression than non-smoking subjects. Several factors make this a complex question. In addition to extracellular trap formation there are other factors which may alter protease expression, the most well-known being anti-proteases such as alpha-1 antitrypsin. Also, patients with emphysema are a heterogeneous group and COPD occurs in only a proportion of smokers. Clearly, further investigation in well-characterised patients with COPD and emphysema would be of interest.

An important feature of extracellular traps is that their expression is degraded by the addition of DNase 1. We used DNase 1 which breaks down extracellular DNA, and found that DNase 1 was highly effective in degrading extracellular trap formation both *in vitro* and *in vivo*. In addition, DNase 1 reduced the numbers of macrophages in the lung tissue induced by cigarette exposure. Proteases induce chemotaxis^{30,31} and the reduction of lung macrophages is consistent with this action. DNase 1 has been shown to reduce lung neutrophil numbers in a mouse model of pancreatitis, but the mechanism is not defined³². Using *in situ* zymography we found that DNase 1 reduced the area of lung with proteolysis. We speculate that this effect may be the result of a combination of inhibition of METs/NETs and decreased macrophage numbers - and potentially also neutrophil numbers. In a mouse model of sickle cell disease, parenterally administered DNase 1 reduced mortality and the primary mechanism was via dismantling of pulmonary NETs³³.

A striking feature of COPD is that inflammation continues after smoking cessation^{1,2}. The factors that drive this inflammation after smoking cessation have not been well defined. Treatment of COPD is only partially effective; no currently available pharmaceutical therapy reduces mortality or reverses the inflammatory process that drives the condition³. Taken together our findings indicate that targeting lung MET/NET expression induced by cigarette smoke by treatment with DNase may potentially have key anti-inflammatory benefits. This can occur via reductions in lung protease expression and macrophage infiltration.

We identified limitations of this study. In patients with cystic fibrosis (CF), DNase 1 (dornase alfa) is given by a nebulized route. In this study we gave DNase 1 by a systemic route as this is standard method that has been used previously and has been demonstrated to have effects on lung NET expression. The parenteral route is the standard method for administering high-dose medication to the lung in patients (e.g. antibiotics and corticosteroids). Administering the DNase by a nasal route would have more variability in the dose given to the mice. Emphysema and COPD are heterogeneous conditions and from this study we are not able to determine, which subgroups of patients are most likely to derive potential benefit from the administration of DNase 1. Finally, we only demonstrated the effect of DNase in short-term smoke exposure models. It will be important to expand this research to assess the effect of DNase 1 in chronic smoke-exposure murine models.

Nebulized DNase 1 is available commercially in the form of dornase alfa which has been used to improve sputum clearance in patients with CF by breaking down extracellular bacterial DNA³⁴. The long-term use of dornase alfa has been demonstrated to be safe, economical and associated with improved clinical outcomes in patients with CF³⁴. However a previous trial in patients with non-CF bronchiectasis did not demonstrate clinical benefit³⁵. Based on our findings we believe that the use of DNase 1 may have a potential role in the treatment of smoking-induced protease imbalance and macrophage infiltration to prevent tissue damage. This needs to be balanced against the inhibition of extracellular trap formation may cause increased risk of respiratory infection (particularly in patients who have microbial airway colonisation). DNase 1 is a potentially powerful immunomodulatory agent for the treatment of patients with COPD but may be most effective for specific indications; perhaps as an addition to antibiotics and corticosteroids for the management of exacerbations or for those patients who have rapidly progressive emphysema.

In summary, we have demonstrated that cigarette smoke induces pulmonary neutrophil and macrophage extracellular trap formation with attendant protease expression. This may be an important mechanism for the development of protease imbalance, a key factor in the pathogenesis of emphysema/COPD and other inflammatory lung conditions. The addition of DNase 1 decreased cigarette smoke-induced MET/NET expression as well as decreasing macrophage numbers and proteolysis in the lung. This proof-of-concept study implies a potential new therapeutic approach in COPD.

Methods

Study subjects and animals. Human studies were approved by the Ethics Committee of Monash Medical Centre (MMC)/Monash Health, Melbourne, Australia. Informed consent was obtained from all subjects. The methods were carried out in accordance with the relevant guidelines and regulations. Murine experiments were approved by the Anatomy and Neuroscience, Pathology, Pharmacology and Physiology AEC Ethics Committee of the University of Melbourne and experiments were conducted as specified (in accordance with) by the Ethics Committee.

We studied patients who were referred to have bronchoscopy at MMC/Monash Health. Bronchoalveolar lavage (BAL) was done to obtain lung macrophages. Neutrophils were also obtained from peripheral blood of healthy control subjects using density gradient isolation.

Study design and methods. To study the effect of cigarette smoke exposure *in vivo*, an established mouse model was used³⁶. In this whole-body smoke exposure model, mice were exposed to cigarette smoke three times a day for 4 days. Sham-exposed mice underwent the same procedure, but without cigarette smoke. On the 4th day, BAL samples were taken and for analysis of whole-lung samples, lung tissue was inflated and fixed. To assess the effect of DNase, DNase 1 was administered twice a day intraperitoneally at a dose of 1×10^4 international units per kg.

An established method was used for the generation of cigarette smoke extract for *in vitro* experiments³⁷. For confocal microscopy cells (macrophages and neutrophils) were seeded onto cover slips. Cells were stimulated with CSE or CSE/DNase for one hour in culture medium (dose of DNase 2 μ g/ml).

We used established flow cytometry methods to measure the production of ROS from neutrophils and macrophages by cleavage of the dye dihydrorhodamine 123 (DHR)¹⁹. To measure the expression of NETs, cells were labelled with the cell impermeable marker SYTOX green and fixable viability dye eFluor 780.

Established methods were used^{11,19,38}. To define the presence of extracellular traps, fixed cells/tissue were permeabilised and then labelled with primary and secondary antibodies. Multiple different protocols were used to define METs and NETs. Images were captured using invert laser-scanning microscopy. Analysis was performed using IMARIS imaging analysis software. The length of extracellular traps was measured using Image J. In lung tissue, macrophages and neutrophils were defined by the number of cells per high-powered field with staining for the specific markers of F4/80 (macrophages) and NE (neutrophils). *In situ* zymography was performed using non-fixed, noninflated lung tissue samples, which were immersed in a highly-quenched fluorescent substrate solution to define areas of the lung with proteolysis.

Statistical analysis. Comparisons between control and cigarette smoke-exposed groups were done using paired or unpaired testing with parametric or non-parametric methods as appropriate. Parametric results are represented graphically by mean and standard error of the mean (SEM), whilst non-parametric results are represented graphically by medians. Statistical analysis was performed using Prism 6 software.

More detailed methods are outlined in the Supplementary Information.

Data availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request and/or; data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References

- Shapiro, S. D. End-stage chronic obstructive pulmonary disease: the cigarette is burned out but inflammation rages on. *Am J Respir Crit Care Med.* **164**, 339–340 (2001).
- Hogg, J. C. *et al.* The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med.* **350**, 2645–2653 (2004).
- Barnes, P. J. New anti-inflammatory targets for chronic obstructive pulmonary disease. *Nat Rev Drug Discov.* **12**, 543–559 (2013).
- Hogg, J. C. & Senior, R. M. Chronic obstructive pulmonary disease -part 2: pathology and biochemistry of emphysema. *Thorax.* **57**, 830–834 (2002).
- Tuder, R. M. & Petrache, I. Pathogenesis of chronic obstructive pulmonary disease. *J Clin Invest.* **122**, 2749–2755 (2012).
- Nichols, D. P. & Chmiel, J. F. Inflammation and its genesis in cystic fibrosis. *Pediatr Pulmonol.* **50**(Suppl 40), S39–56 (2015).
- King, P. T. The pathophysiology of bronchiectasis. *Int J Chronic Obstruct Pulm Dis.* **4**, 411–419 (2009).
- Sinden, N. J. *et al.* alpha-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. *Am J Physiol. Lung Cell Mol Physiol.* **308**, L179–190 (2015).
- Kuhn, C., Yu, S. Y., Chraplyvy, M., Linder, H. E. & Senior, R. M. The induction of emphysema with elastase. II. Changes in connective tissue. *Lab Invest.* **34**, 372–380 (1976).
- Hautamaki, R. D., Kobayashi, D. K., Senior, R. M. & Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. *Science.* **277**, 2002–2004 (1997).
- Brinkmann, V. & Zychlinsky, A. Neutrophil extracellular traps: is immunity the second function of chromatin? *J Cell Biol.* **198**, 773–783 (2012).
- Cheng, O. Z. & Palaniyar, N. NET balancing: a problem in inflammatory lung diseases. *Frontiers Immunol.* **4**, 1 (2013).
- Fuchs, T. A. *et al.* Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol.* **176**, 231–241 (2007).
- Papayannopoulos, V., Metzler, K. D., Hakkim, A. & Zychlinsky, A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J Cell Biol.* **191**, 677–691 (2010).
- Wang, Y. *et al.* Histone hypercitullination mediates chromatin decondensation and neutrophil extracellular trap formation. *J Cell Biol.* **184**, 205–213 (2009).
- Rohrbach, A. S., Slade, D. J., Thompson, P. R. & Mowen, K. A. Activation of PAD4 in NET formation. *Frontiers Immunol.* **3**, 360 (2012).
- Lewis, H. D. *et al.* Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. *Nat Chem Biol.* **11**, 189–191 (2015).
- Boe, D. M., Curtis, B. J., Chen, M. M., Ippolito, J. A. & Kovacs, E. J. Extracellular traps and macrophages: new roles for the versatile phagocyte. *J Leukocyte Biol.* **97**, 1023–1035 (2015).

19. King, P. T. *et al.* Nontypeable *Haemophilus influenzae* induces sustained lung oxidative stress and protease expression. *PLoS one*. **10**, e0120371 (2015).
20. Vandooren, J., Geurts, N., Martens, E., Van den Steen, P. E. & Opdenakker, G. Zymography methods for visualizing hydrolytic enzymes. *Nat Methods*. **10**, 211–220 (2013).
21. Ito, I. *et al.* Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. *Am J Respir Crit Care Med*. **172**, 1378–1382 (2005).
22. Brinkmann, V. *et al.* Neutrophil extracellular traps kill bacteria. *Science*. **303**, 1532–1535 (2004).
23. Jorch, S. K. & Kubers, P. An emerging role for neutrophil extracellular traps in noninfectious disease. *Nat Med*. **23**, 279–287 (2017).
24. Obermayer, A. *et al.* New aspects on the structure of neutrophil extracellular traps from chronic obstructive pulmonary disease and *in vitro* generation. *PLoS one*. **9**, e97784 (2014).
25. Pedersen, F. *et al.* Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients. *Respir Med*. **109**, 1360–1362 (2015).
26. Wright, T. K. *et al.* Neutrophil extracellular traps are associated with inflammation in chronic airway disease. *Respirology*. **21**, 467–475 (2016).
27. Hosseinzadeh, A., Thompson, P. R., Segal, B. H. & Urban, C. F. Nicotine induces neutrophil extracellular traps. *J Leukocyte Biol*. **100**, 1105–1112 (2016).
28. Lee, J. *et al.* Nicotine drives neutrophil extracellular traps formation and accelerates collagen-induced arthritis. *Rheumatology*. **56**, 644–653 (2017).
29. Wu, H., Li, L. & Su, X. Vagus nerve through alpha7 nAChR modulates lung infection and inflammation: models, cells, and signals. *BioMed Res Int* **2014**, 283525 (2014).
30. Hunninghake, G. W. *et al.* Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. *Science*. **212**, 925–927 (1981).
31. Weathington, N. M. *et al.* A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. *Nat Med* **12**, 317–323 (2006).
32. Merza, M. *et al.* Neutrophil Extracellular Traps Induce Trypsin Activation, Inflammation, and Tissue Damage in Mice With Severe Acute Pancreatitis. *Gastroenterology*. **149**, 1920–1931 e1928 (2015).
33. Chen, G. *et al.* Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. *Blood*. **123**, 3818–3827 (2014).
34. Konstan, M. W. & Ratjen, F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. *J Cystic Fibrosis*. **11**, 78–83 (2012).
35. O'Donnell, A. E., Barker, A. F., Ilowite, J. S. & Fick, R. B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. *Chest*. **113**, 1329–1334 (1998).
36. Vlahos, R. *et al.* Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. *Am J Physiol. Lung Cell Mol Physiol*. **290**, L931–945 (2006).
37. Ruwanpura, S. M. *et al.* Interleukin-6 promotes pulmonary emphysema associated with apoptosis in mice. *Am J Respir Cell Mol Biol*. **45**, 720–730 (2011).
38. O'Sullivan, K. M. *et al.* Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. *Kidney Int*. **88**, 1030–1046 (2015).

Acknowledgements

The authors would like to thank the staff of Clinical Immunology at Monash Health, Alex Fulcher, Kirstin Elgass and Camden Lo of Monash Micro Imaging (MMI) for help with the taking of the confocal microscopy pictures and the authors acknowledge the MMI facilities of Monash University. The authors acknowledge the facilities and scientific and technical assistance of the Monash Histology Platform. This study was supported by a Monash University Strategic Grant and the Monash Lung and Sleep Institute.

Author Contributions

P.T.K., R.S., K.O.S., J.C., L.D., S.R., S.L., G.B., B.T. performed laboratory work, M.W.F., B.J. provided human B.A.L. samples, S.S. provided tools, P.T.K., R.S., K.O.S., M.F. analysed the data, P.T.K., R.S., K.O.S., G.P.A., S.R.H., P.G.B. designed the study, P.T.K. wrote the manuscript and all authors contributed to the critical review of the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-12474-5>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017